A decision tree for the genetic diagnosis of deficiency of adenosine deaminase 2 (DADA2): a French reference centres experience

Mélanie Rama, Claire Duflos, Isabelle Melki, Didier Bessis, Axelle Bonhomme, Hélène Martin, Diane Doummar, Stéphanie Valence, Diana Rodriguez, Emilie Carme, David Genevieve, Ketil Heimdal, Antonella Insalaco, Nathalie Franck, Viviane Queyrel-Moranne, Nathalie Tieulie, Jonathan London, Florence Uettwiller, Sophie Georgin-Lavialle, Alexandre BelotIsabelle Koné-Paut, Véronique Hentgen, Guilaine Boursier, Isabelle Touitou, Guillaume Sarrabay

Research output: Contribution to journalArticle

Abstract

Deficiency of adenosine deaminase 2 (DADA2) is a recently described autoinflammatory disorder. Genetic analysis is required to confirm the diagnosis. We aimed to describe the identifying symptoms and genotypes of patients referred to our reference centres and to improve the indications for genetic testing. DNA from 66 patients with clinically suspected DADA2 were sequenced by Sanger or next-generation sequencing. Detailed epidemiological, clinical and biological features were collected by use of a questionnaire and were compared between patients with and without genetic confirmation of DADA2. We identified 13 patients (19.6%) carrying recessively inherited mutations in ADA2 that were predicted to be deleterious. Eight patients were compound heterozygous for mutations. Seven mutations were novel (4 missense variants, 2 predicted to affect mRNA splicing and 1 frameshift). The mean age of the 13 patients with genetic confirmation was 12.7 years at disease onset and 20.8 years at diagnosis. Phenotypic manifestations included fever (85%), vasculitis (85%) and neurological disorders (54%). Features best associated with a confirmatory genotype included fever with neurologic or cutaneous attacks (odds ratio [OR] 10.71, p = 0.003 and OR 10.9, p < 0.001), fever alone (OR 8.1, p = 0.01), and elevated C-reactive protein (CRP) level with neurologic involvement (OR 6.63, p = 0.017). Our proposed decision tree may help improve obtaining genetic confirmation of DADA2 in the context of autoinflammatory symptoms. Prerequisites for quick and low-cost Sanger analysis include one typical cutaneous or neurological sign, one marker of inflammation (fever or elevated CRP level), and recurrent or chronic attacks in adults.

Original languageEnglish
Pages (from-to)960-971
Number of pages12
JournalEuropean Journal of Human Genetics
Volume26
Issue number7
DOIs
Publication statusPublished - Jul 2018

Fingerprint

Decision Trees
Fever
Odds Ratio
C-Reactive Protein
Nervous System
Mutation
Genotype
Skin
Genetic Testing
Vasculitis
Nervous System Diseases
Severe combined immunodeficiency due to adenosine deaminase deficiency
Inflammation
Costs and Cost Analysis
Messenger RNA
DNA

Cite this

A decision tree for the genetic diagnosis of deficiency of adenosine deaminase 2 (DADA2) : a French reference centres experience. / Rama, Mélanie; Duflos, Claire; Melki, Isabelle; Bessis, Didier; Bonhomme, Axelle; Martin, Hélène; Doummar, Diane; Valence, Stéphanie; Rodriguez, Diana; Carme, Emilie; Genevieve, David; Heimdal, Ketil; Insalaco, Antonella; Franck, Nathalie; Queyrel-Moranne, Viviane; Tieulie, Nathalie; London, Jonathan; Uettwiller, Florence; Georgin-Lavialle, Sophie; Belot, Alexandre; Koné-Paut, Isabelle; Hentgen, Véronique; Boursier, Guilaine; Touitou, Isabelle; Sarrabay, Guillaume.

In: European Journal of Human Genetics, Vol. 26, No. 7, 07.2018, p. 960-971.

Research output: Contribution to journalArticle

Rama, M, Duflos, C, Melki, I, Bessis, D, Bonhomme, A, Martin, H, Doummar, D, Valence, S, Rodriguez, D, Carme, E, Genevieve, D, Heimdal, K, Insalaco, A, Franck, N, Queyrel-Moranne, V, Tieulie, N, London, J, Uettwiller, F, Georgin-Lavialle, S, Belot, A, Koné-Paut, I, Hentgen, V, Boursier, G, Touitou, I & Sarrabay, G 2018, 'A decision tree for the genetic diagnosis of deficiency of adenosine deaminase 2 (DADA2): a French reference centres experience', European Journal of Human Genetics, vol. 26, no. 7, pp. 960-971. https://doi.org/10.1038/s41431-018-0130-6
Rama, Mélanie ; Duflos, Claire ; Melki, Isabelle ; Bessis, Didier ; Bonhomme, Axelle ; Martin, Hélène ; Doummar, Diane ; Valence, Stéphanie ; Rodriguez, Diana ; Carme, Emilie ; Genevieve, David ; Heimdal, Ketil ; Insalaco, Antonella ; Franck, Nathalie ; Queyrel-Moranne, Viviane ; Tieulie, Nathalie ; London, Jonathan ; Uettwiller, Florence ; Georgin-Lavialle, Sophie ; Belot, Alexandre ; Koné-Paut, Isabelle ; Hentgen, Véronique ; Boursier, Guilaine ; Touitou, Isabelle ; Sarrabay, Guillaume. / A decision tree for the genetic diagnosis of deficiency of adenosine deaminase 2 (DADA2) : a French reference centres experience. In: European Journal of Human Genetics. 2018 ; Vol. 26, No. 7. pp. 960-971.
@article{ceba8b31fdcd44ea97d7ec2703a76277,
title = "A decision tree for the genetic diagnosis of deficiency of adenosine deaminase 2 (DADA2): a French reference centres experience",
abstract = "Deficiency of adenosine deaminase 2 (DADA2) is a recently described autoinflammatory disorder. Genetic analysis is required to confirm the diagnosis. We aimed to describe the identifying symptoms and genotypes of patients referred to our reference centres and to improve the indications for genetic testing. DNA from 66 patients with clinically suspected DADA2 were sequenced by Sanger or next-generation sequencing. Detailed epidemiological, clinical and biological features were collected by use of a questionnaire and were compared between patients with and without genetic confirmation of DADA2. We identified 13 patients (19.6{\%}) carrying recessively inherited mutations in ADA2 that were predicted to be deleterious. Eight patients were compound heterozygous for mutations. Seven mutations were novel (4 missense variants, 2 predicted to affect mRNA splicing and 1 frameshift). The mean age of the 13 patients with genetic confirmation was 12.7 years at disease onset and 20.8 years at diagnosis. Phenotypic manifestations included fever (85{\%}), vasculitis (85{\%}) and neurological disorders (54{\%}). Features best associated with a confirmatory genotype included fever with neurologic or cutaneous attacks (odds ratio [OR] 10.71, p = 0.003 and OR 10.9, p < 0.001), fever alone (OR 8.1, p = 0.01), and elevated C-reactive protein (CRP) level with neurologic involvement (OR 6.63, p = 0.017). Our proposed decision tree may help improve obtaining genetic confirmation of DADA2 in the context of autoinflammatory symptoms. Prerequisites for quick and low-cost Sanger analysis include one typical cutaneous or neurological sign, one marker of inflammation (fever or elevated CRP level), and recurrent or chronic attacks in adults.",
author = "M{\'e}lanie Rama and Claire Duflos and Isabelle Melki and Didier Bessis and Axelle Bonhomme and H{\'e}l{\`e}ne Martin and Diane Doummar and St{\'e}phanie Valence and Diana Rodriguez and Emilie Carme and David Genevieve and Ketil Heimdal and Antonella Insalaco and Nathalie Franck and Viviane Queyrel-Moranne and Nathalie Tieulie and Jonathan London and Florence Uettwiller and Sophie Georgin-Lavialle and Alexandre Belot and Isabelle Kon{\'e}-Paut and V{\'e}ronique Hentgen and Guilaine Boursier and Isabelle Touitou and Guillaume Sarrabay",
year = "2018",
month = "7",
doi = "10.1038/s41431-018-0130-6",
language = "English",
volume = "26",
pages = "960--971",
journal = "European Journal of Human Genetics",
issn = "1018-4813",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - A decision tree for the genetic diagnosis of deficiency of adenosine deaminase 2 (DADA2)

T2 - a French reference centres experience

AU - Rama, Mélanie

AU - Duflos, Claire

AU - Melki, Isabelle

AU - Bessis, Didier

AU - Bonhomme, Axelle

AU - Martin, Hélène

AU - Doummar, Diane

AU - Valence, Stéphanie

AU - Rodriguez, Diana

AU - Carme, Emilie

AU - Genevieve, David

AU - Heimdal, Ketil

AU - Insalaco, Antonella

AU - Franck, Nathalie

AU - Queyrel-Moranne, Viviane

AU - Tieulie, Nathalie

AU - London, Jonathan

AU - Uettwiller, Florence

AU - Georgin-Lavialle, Sophie

AU - Belot, Alexandre

AU - Koné-Paut, Isabelle

AU - Hentgen, Véronique

AU - Boursier, Guilaine

AU - Touitou, Isabelle

AU - Sarrabay, Guillaume

PY - 2018/7

Y1 - 2018/7

N2 - Deficiency of adenosine deaminase 2 (DADA2) is a recently described autoinflammatory disorder. Genetic analysis is required to confirm the diagnosis. We aimed to describe the identifying symptoms and genotypes of patients referred to our reference centres and to improve the indications for genetic testing. DNA from 66 patients with clinically suspected DADA2 were sequenced by Sanger or next-generation sequencing. Detailed epidemiological, clinical and biological features were collected by use of a questionnaire and were compared between patients with and without genetic confirmation of DADA2. We identified 13 patients (19.6%) carrying recessively inherited mutations in ADA2 that were predicted to be deleterious. Eight patients were compound heterozygous for mutations. Seven mutations were novel (4 missense variants, 2 predicted to affect mRNA splicing and 1 frameshift). The mean age of the 13 patients with genetic confirmation was 12.7 years at disease onset and 20.8 years at diagnosis. Phenotypic manifestations included fever (85%), vasculitis (85%) and neurological disorders (54%). Features best associated with a confirmatory genotype included fever with neurologic or cutaneous attacks (odds ratio [OR] 10.71, p = 0.003 and OR 10.9, p < 0.001), fever alone (OR 8.1, p = 0.01), and elevated C-reactive protein (CRP) level with neurologic involvement (OR 6.63, p = 0.017). Our proposed decision tree may help improve obtaining genetic confirmation of DADA2 in the context of autoinflammatory symptoms. Prerequisites for quick and low-cost Sanger analysis include one typical cutaneous or neurological sign, one marker of inflammation (fever or elevated CRP level), and recurrent or chronic attacks in adults.

AB - Deficiency of adenosine deaminase 2 (DADA2) is a recently described autoinflammatory disorder. Genetic analysis is required to confirm the diagnosis. We aimed to describe the identifying symptoms and genotypes of patients referred to our reference centres and to improve the indications for genetic testing. DNA from 66 patients with clinically suspected DADA2 were sequenced by Sanger or next-generation sequencing. Detailed epidemiological, clinical and biological features were collected by use of a questionnaire and were compared between patients with and without genetic confirmation of DADA2. We identified 13 patients (19.6%) carrying recessively inherited mutations in ADA2 that were predicted to be deleterious. Eight patients were compound heterozygous for mutations. Seven mutations were novel (4 missense variants, 2 predicted to affect mRNA splicing and 1 frameshift). The mean age of the 13 patients with genetic confirmation was 12.7 years at disease onset and 20.8 years at diagnosis. Phenotypic manifestations included fever (85%), vasculitis (85%) and neurological disorders (54%). Features best associated with a confirmatory genotype included fever with neurologic or cutaneous attacks (odds ratio [OR] 10.71, p = 0.003 and OR 10.9, p < 0.001), fever alone (OR 8.1, p = 0.01), and elevated C-reactive protein (CRP) level with neurologic involvement (OR 6.63, p = 0.017). Our proposed decision tree may help improve obtaining genetic confirmation of DADA2 in the context of autoinflammatory symptoms. Prerequisites for quick and low-cost Sanger analysis include one typical cutaneous or neurological sign, one marker of inflammation (fever or elevated CRP level), and recurrent or chronic attacks in adults.

U2 - 10.1038/s41431-018-0130-6

DO - 10.1038/s41431-018-0130-6

M3 - Article

C2 - 29681619

VL - 26

SP - 960

EP - 971

JO - European Journal of Human Genetics

JF - European Journal of Human Genetics

SN - 1018-4813

IS - 7

ER -